Although the prevailing view is that immune cells such as CD8+ T cells, CD4+ T cells, and NK cells perform anti-tumor functions in tumor therapy, due to tumor heterogeneity, these immune cells may be resistant to tumor therapy by regulating core immune checkpoint proteins and chemokines [32,33]. The gene discussed is CD8A; the disease is neoplasm.